Evidence map›Paper›PMID 39085955›Full record

ArticleActa neuropathologica communications2024

Pure argyrophilic grain disease revisited: independent effects on limbic, neocortical, and striato-pallido-nigral degeneration and the development of dementia in a series with a low to moderate Braak stage.

Osamu Yokota, Tomoko Miki, Hanae Nakashima-Yasuda, Hideki Ishizu, Takashi Haraguchi, Chikako Ikeda, Masato Hasegawa, Akinori Miyashita, Takeshi Ikeuchi, Naoto Nishikawa and 4 more

Abstract read
In one paragraph

Article in Acta neuropathologica communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Osamu YokotaDepartment of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama, 700-8558, Japan. oyokota1@yahoo.co.jp.ORCID 0000-0003-2990-7952
Tomoko MikiDepartment of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama, 700-8558, Japan.
Hanae Nakashima-YasudaOkayama University Medical School, Okayama, Japan.
Hideki IshizuOkayama University Medical School, Okayama, Japan.
Takashi HaraguchiDepartment of Neurology, National Hospital Organization Minami-Okayama Medical Center, Okayama, Japan.
Chikako IkedaOkayama University Medical School, Okayama, Japan.
Masato HasegawaDementia Research Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Akinori MiyashitaDepartment of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan.
Takeshi IkeuchiDepartment of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan.
Naoto NishikawaDepartment of Neuropsychiatry, Okayama University Hospital, Okayama, Japan.
Shintaro TakenoshitaDepartment of Neuropsychiatry, Okayama University Hospital, Okayama, Japan.
Koichiro SudoDepartment of Psychiatry, Tosa Hospital, Kochi, Japan.
Seishi TeradaDepartment of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama, 700-8558, Japan.
Manabu TakakiDepartment of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama, 700-8558, Japan.

Funding

Grants-in-Aid for Scientific Research (C) from the Japanese Ministry of Education, Culture, Sports, Science and Technology MEXT KAKENHI Grant No. 23K07035Grants-in-Aid for Scientific Research (C) from the Japanese Ministry of Education, Culture, Sports, Science and Technology MEXT KAKENHI Grant No. 23K10450the Strategic Research Program for Brain Sciences from the Japan Agency for Medical Research and Development (AMED) JP24dk0207060the Strategic Research Program for Brain Sciences from the Japan Agency for Medical Research and Development (AMED) JP24wm0425019
6 · The paper itself

Abstract

Agyrophilic grains (AGs) are age-related limbic-predominant lesions in which four-repeat tau is selectively accumulated. Because previous methodologically heterogeneous studies have demonstrated inconsistent findings on the relationship between AGs and dementia, whether AGs affect cognitive function remains unclear. To address this question, we first comprehensively evaluated the distribution and quantity of Gallyas-positive AGs and the severity of neuronal loss in the limbic, neocortical, and subcortical regions in 30 cases of pure argyrophilic grain disease (pAGD) in Braak stages I-IV and without other degenerative diseases, and 34 control cases that had only neurofibrillary tangles with Braak stages I-IV and no or minimal Aβ deposits. Then, we examined whether AGs have independent effects on neuronal loss and dementia by employing multivariate ordered logistic regression and binomial logistic regression. Of 30 pAGD cases, three were classified in diffuse form pAGD, which had evident neuronal loss not only in the limbic region but also in the neocortex and subcortical nuclei. In all 30 pAGD cases, neuronal loss developed first in the amygdala, followed by temporo-frontal cortex, hippocampal CA1, substantia nigra, and finally, the striatum and globus pallidus with the progression of Saito AG stage. In multivariate analyses of 30 pAGD and 34 control cases, the Saito AG stage affected neuronal loss in the amygdala, hippocampal CA1, temporo-frontal cortex, striatum, globus pallidus, and substantia nigra independent of the age, Braak stage, and limbic-predominant age-related TDP-43 encephalopathy (LATE-NC) stage. In multivariate analyses of 23 pAGD and 28 control cases that lacked two or more lacunae and/or one or more large infarctions, 100 or more AGs per × 400 visual field in the amygdala (OR 10.02, 95% CI 1.12-89.43) and hippocampal CA1 (OR 12.22, 95% CI 1.70-87.81), and the presence of AGs in the inferior temporal cortex (OR 8.18, 95% CI 1.03-65.13) affected dementia independent of age, moderate Braak stages (III-IV), and LATE-NC. Given these findings, the high density of limbic AGs and the increase of AGs in the inferior temporal gyrus may contribute to the occurrence of dementia through neuronal loss, at least in cases in a low to moderate Braak stage.

Indexed as

DementiaNeocortexAgedAged, 80 and overFemaleGlobus PallidusHumansLimbic SystemMaleMiddle AgedNeurodegenerative DiseasesNeurofibrillary TanglesSubstantia NigraArgyrophilic grainGlobus pallidusHippocampal sclerosisStriatumSubstantia nigraSubthalamic nucleus

Identifiers

PMID39085955
PMCPMC11290173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.